Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P35557: Variant p.Val226Met

Hexokinase-4
Gene: GCK
Feedback?
Variant information Variant position: help 226 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Valine (V) to Methionine (M) at position 226 (V226M, p.Val226Met). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In MODY2; no effect on stability; decreased glucokinase activity; decreased affinity for glucose. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 226 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 465 The length of the canonical sequence.
Location on the sequence: help TVATMISCYYEDHQCEVGMI V GTGCNACYMEEMQNVELVEG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         TVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEG

Mouse                         TVATMISCYYEDRQCEVGMIVGTGCNACYMEEMQNVELVEG

Rat                           TVATMISCYYEDRQCEVGMIVGTGCNACYMEEMQNVELVEG

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 465 Hexokinase-4
Domain 10 – 454 Hexokinase
Region 204 – 443 Hexokinase large subdomain
Binding site 228 – 228
Binding site 231 – 231
Mutagenesis 211 – 211 I -> F. Increased glucokinase activity based on measure of catalytic efficiency. Increased affinity for glucose.
Mutagenesis 214 – 214 Y -> A. Increased glucokinase activity based on measure of catalytic efficiency. Increased affinity for glucose. No effect on affinity for ATP.
Mutagenesis 215 – 215 Y -> A. Increased glucokinase activity based on measure of catalytic efficiency. Increased affinity for glucose. Loss of inhibition by GCKR. No effect on affinity for ATP.
Beta strand 220 – 237



Literature citations
Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families.
Velho G.; Blanche H.; Vaxillaire M.; Bellanne-Chantelot C.; Pardini V.C.; Timsit J.; Passa P.; Deschamps I.; Robert J.-J.; Weber I.T.; Marotta D.; Pilkis S.J.; Lipkind G.M.; Bell G.I.; Froguel P.;
Diabetologia 40:217-224(1997)
Cited for: VARIANTS MODY2 SER-53; ALA-80; ARG-137; PRO-168; 186-ARG--GLN-465 DEL; THR-210; ARG-213; MET-226; 248-GLU--GLN-465 DEL; ARG-261; LEU-336; 360-SER--GLN-465 DEL AND MET-367; Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.
Vits L.; Beckers D.; Craen M.; de Beaufort C.; Vanfleteren E.; Dahan K.; Nollet A.; Vanhaverbeke G.; Imschoot S.V.; Bourguignon J.P.; Beauloye V.; Storm K.; Massa G.; Giri M.; Nobels F.; De Schepper J.; Rooman R.; Van den Bruel A.; Mathieu C.; Wuyts W.;
Clin. Genet. 70:355-359(2006)
Cited for: VARIANTS MODY2 TRP-36; TYR-129; LEU-152; VAL-188; TRP-191; ARG-202; SER-223; MET-226; HIS-231; PHE-315; THR-378; PHE-434; TRP-441 AND GLN-447; Phenotypic severity of homozygous GCK mutations causing neonatal or childhood-onset diabetes is primarily mediated through effects on protein stability.
Raimondo A.; Chakera A.J.; Thomsen S.K.; Colclough K.; Barrett A.; De Franco E.; Chatelas A.; Demirbilek H.; Akcay T.; Alawneh H.; Flanagan S.E.; Van De Bunt M.; Hattersley A.T.; Gloyn A.L.; Ellard S.;
Hum. Mol. Genet. 23:6432-6440(2014)
Cited for: VARIANTS PNDM1 LYS-40; CYS-43; ASP-50; ARG-72; THR-151; PRO-164; ALA-168; ARG-169; ARG-261; THR-393; LEU-397; LEU-441 AND THR-449; CHARACTERIZATION OF VARIANTS PNDM1 LYS-40; CYS-43; ASP-50; ARG-72; ALA-168; ARG-261; THR-393; LEU-397; LEU-441 AND THR-449; VARIANTS MODY2 ASN-160 AND MET-226; CHARACTERIZATION OF VARIANT MODY2 ASN-160 AND MET-226; FUNCTION; CATALYTIC ACTIVITY;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.